1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.
2.
Marques AD, Moura AR, Hora EC, et al. Analysis of breast cancer survival in a northeastern Brazilian state based on prognostic factors: A retrospective cohort study. PLoS One 2022; 17: e0263222.
3.
Hjerkind KV, Johansson ALV, Trewin CB, et al. Incidence of breast cancer subtypes in immigrant and non-immigrant women in Norway. Breast Cancer Res 2022; 24: 4.
4.
McCarthy AM, Liu Y, Ehsan S, et al. Validation of Breast Cancer Risk Models by Race/Ethnicity, Family History and Molecular Subtypes. Cancers (Basel) 2021; 14: 45.
5.
Tagliabue G, Fabiano S, Contiero P, et al. Molecular Subtypes, Metastatic Pattern and Patient Age in Breast Cancer: An Analysis of Italian Network of Cancer Registries (AIRTUM) Data.
6.
J Clin Med 2021; 10: 5873.
7.
Lorona NC, Malone KE, Li CI. Racial/ethnic disparities in risk of breast cancer mortality by molecular subtype and stage at diagnosis. Breast Cancer Res Treat 2021; 190: 549-558.
8.
Howard FM, Olopade OI. Epidemiology of Triple-Negative Breast Cancer: A Review. Cancer J 2021; 27: 8-16.
9.
DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin 2019; 69: 438-451.
10.
Focke CM, van Diest PJ, Decker T. St Gallen 2015 subtyping of luminal breast cancers: impact of different Ki67-based proliferation assessment methods. Breast Cancer Res Treat 2016; 159: 257-263.
11.
WHO Classification of Tumours of the Breast. Edited by Sunil R Lakhani, Jan O Ellis, Stuart J Schnitt, Puay Hoon Tan, Marc J van de Vijver. IARC, Lyon 2012.
12.
WHO Classification of Tumours Editorial Board. Breast tumours. Lyon (France) International Agency for Research of Cancer 2019.
13.
Liao HY, Zhang WW, Sun JY, et al. The Clinicopathological Features and Survival Outcomes of Different Histological Subtypes in Triple-negative Breast Cancer. J Cancer 2018; 9: 296-303.
14.
Wang X, Xu Y, Guo S, et al. T1-2N1M0 triple-negative breast cancer patients from the SEER database showed potential benefit from post-mastectomy radiotherapy. Oncol Lett 2020; 19: 735-744.
15.
Geyer FC, Pareja F, Weigelt B, et al. The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions. Am J Pathol 2017; 187: 2139-2151.
16.
Ridolfi RL, Rosen PP, Port A, Kinne D, Miké V. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer 1977; 40:1365-85.
17.
Weisman PS, Ng CK, Brogi E, et al. Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. Mod Pathol 2016; 29: 476-488.
18.
D'Arcy C, Quinn CM. Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast. J Clin Pathol 2019; 72: 7-11.
19.
Sun X, Zuo K, Yao Q, et al. Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas. Mod Pathol 2020; 33: 2473-2482.
20.
Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. Hum Pathol 1989; 20: 628-635.
21.
Rakha EA et al Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study. Br J Cancer 2015; 112: 283-289.
22.
Edenfield J, Schammel C, Collins J, et al. Metaplastic Breast Cancer: Molecular Typing and Identification of Potential Targeted Therapies at a Single Institution. Clin Breast Cancer 2017; 17: e1-e10.
23.
Song Y, Liu X, Zhang G, et al. Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators. World J Surg Oncol 2013; 11: 129.
24.
Zhang Y, Lv F, Yang Y, et al. Clinicopathological Features and Prognosis of Metaplastic Breast Carcinoma: Experience of a Major Chinese Cancer Center. PLoS One 2015; 10: e0131409.
25.
Bergeron A, MacGrogan G, Bertaut A, et al. Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations. Mod Pathol 2021; 34: 1282-1296.
26.
Pareja F, Geyer FC, Marchiò C, et al. Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. NPJ Breast Cancer 2016; 2: 16036.
27.
Ro JY, Silva EG, Gallager HS. Adenoid cystic carcinoma of the breast. Hum Pathol 1987; 18: 1276-1281.
28.
Miyai K, Schwartz MR, Divatia MK, et al. Adenoid cystic carcinoma of breast: Recent advances. World J Clin Cases. 2014; 2: 732-741.
29.
Marco V, Garcia F, Rubio IT, et al. Adenoid cystic carcinoma and basaloid carcinoma of the breast: A clinicopathological study. Rev Esp Patol 2021; 54: 242-249.
30.
Gong P, Xia C, Yang Y, et al. Clinicopathologic profiling and oncologic outcomes of secretory carcinoma of the breast. Sci Rep 2021; 11: 14738.
31.
Vasudev P, Onuma K. Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression. Arch Pathol Lab Med 2011; 135: 1606-1610.
32.
Horowitz DP, Sharma CS, Connolly E et al. Secretory carcinoma of the breast: results from the survival, epidemiology and end results database. Breast 2012; 21: 350-353.
33.
Piscuoglio S, Hodi Z, Katabi N, et al. Are acinic cell carcinomas of the breast and salivary glands distinct diseases? Histopathology 2015; 67: 529-537.
34.
Conlon N, Sadri N, Corben AD, et al. Acinic cell carcinoma of breast: morphologic and immunohistochemical review of a rare breast cancer subtype. Hum Pathol 2016; 51: 16-24.
35.
Trihia HJ, Valavanis C, Novkovic N, et al. Polymorphous adenocarcinoma of the breast-an exceptionally rare entity: Clinicopathological description of a case and brief review. Breast
36.
J 2020; 26: 261-264.
37.
Foschini MP, Morandi L, Asioli S, et al. The morphological spectrum of salivary gland type tumours of the breast. Pathology 2017; 49: 215-227.
38.
Acs G, Simpson JF, Bleiweiss IJ, et al. Microglandular adenosis with transition into adenoid cystic carcinoma of the breast. Am J Surg Pathol 2003; 27: 1052-1060.
39.
Guerini-Rocco E, Piscuoglio S, Ng CK, et al. Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations. J Pathol 2016; 238: 677-688.
40.
Schwartz CJ, Dolgalev I, Yoon E, et al. Microglandular adenosis is an advanced precursor breast lesion with evidence of molecular progression to matrix-producing metaplastic carcinoma. Hum Pathol 2019; 85: 65-71.
41.
Van Hoeven KH, Drudis T, Cranor ML, et al. Low-grade adenosquamous carcinoma of the breast. A clinocopathologic study of 32 cases with ultrastructural analysis. Am J Surg Pathol 1993; 17: 248-258.
42.
Zhao Y, Gong X, Li N, et al. Fibromatosis-like metaplastic carcinoma of breast: a challenge for clinicopathologic diagnosis. Int J Clin Exp Pathol 2018; 11: 3691-3696.
43.
Zhou X, Wu X, Wang L, et al. Metaplastic breast carcinoma: a retrospective study of 26 cases. Int J Clin Exp Pathol 2021; 14: 355-362.
44.
Pia-Foschini M, Reis-Filho JS, Eusebi V, Lakhani SR. Salivary gland-like tumours of the breast: surgical and molecular pathology. J Clin Pathol 2003; 56: 497-506.
45.
Cheng M, Geng C, Tang T, Song Z. Mucoepidermoid carcinoma of the breast: Four case reports and review of the literature. Medicine (Baltimore). 2017; 96: e9385.
46.
Haefliger S, Muenst S, Went P, et al. Tall cell carcinoma of the breast with reversed polarity (TCCRP) with mutations in the IDH2 and PIK3CA genes: a case report. Mol Biol Rep 2020; 47: 4917-4921.
47.
Zhang X, Wu H, Wang Z, et al. Tall cell carcinoma of the breast with reverse polarity: case report with gene sequencing and literature review. Gland Surg 2021; 10: 837-843.
48.
Wei Y, Ding L, Song X, et al. Tall cell carcinoma with reversed polarity: case report with gene sequencing and literature review. Gland Surg 2021; 10: 3147-3315.
49.
Rakha E, Tan PH, Ellis I, et al. Adenomyoepithelioma of the breast: a proposal for classification. Histopathology 2021; 79: 465-479.
50.
Dai D, Jin H, Wang X. Nomogram for predicting survival in triple-negative breast cancer patients with histology of infiltrating duct carcinoma: a population-based study. Am J Cancer Res 2018; 8: 1576-1585.
51.
Nelson RA, Guye ML, Luu T, et al. Survival outcomes of metaplastic breast cancer patients: results from a US population-based analysis. Ann Surg Oncol 2015; 22: 24-31.
52.
Lee H, Jung SY, Ro JY, et al. Metaplastic breast cancer: clinicopathological features and its prognosis. J Clin Pathol 2012; 65: 441-446.
53.
Song Y, Liu X, Zhang G, et al. Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators. World J Surg Oncol 2013; 11: 129.
54.
El Zein D, Hughes M, Kumar S, et al. Metaplastic Carcinoma of the Breast Is More Aggressive Than Triple-negative Breast Cancer: A Study From a Single Institution and Review of Literature. Clin Breast Cancer 2017; 17: 382-391.
55.
Lai HW, Tseng LM, Chang TW, et al. The prognostic significance of metaplastic carcinoma of the breast (MCB) - a case controlled comparison study with infiltrating ductal carcinoma. Breast 2013; 22: 968-973.
56.
Erber R, Hartmann A. Understanding PD-L1 Testing in Breast Cancer: A Practical Approach. Breast Care (Basel) 2020; 15: 481-490.
57.
Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, et al. The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. J Pathol 2020; 250: 667-684.
58.
Vranic S, Cyprian FS, Gatalica Z, Palazzo J. PD-L1 status in breast cancer: Current view and perspectives. Semin Cancer Biol 2021; 72: 146-154 .
